PAI
Palo Alto Investors Portfolio holdings
AUM
$470M
This Quarter Return
+24.47%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$1.91B
AUM Growth
+$1.91B
(+4.7%)
Cap. Flow
-$225M
Cap. Flow
% of AUM
-11.82%
Top 10 Holdings %
Top 10 Hldgs %
76.45%
Holding
46
New
3
Increased
22
Reduced
1
Closed
5
Top Buys
| 1 |
Biogen
BIIB
|
$57.4M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$37M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$25.1M |
| 4 |
eHealth
EHTH
|
$21.6M |
| 5 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$19.2M |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$413M |
| 2 |
AMAG
AMAG Pharmaceuticals, Inc.
AMAG
|
$28.2M |
| 3 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
$1.55M |
| 4 |
Evolus
EOLS
|
$1.04M |
| 5 |
AIMT
Aimmune Therapeutics, Inc.
AIMT
|
$682K |
Sector Composition
| 1 | Healthcare | 97.42% |
| 2 | Financials | 2.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
STAAR Surgical
STAA
$1.36B
| $226M | 11.83% | 2,849,348 +57,655 | +2% | +$4.57M |
|
2
Insmed
INSM
$28.8B
| $203M | 10.66% | 6,105,980 +73,024 | +1% | +$2.43M |
|
|
3
BioMarin Pharmaceuticals
BMRN
$11.2B
| $189M | 9.91% | 2,155,050 +422,500 | +24% | +$37M |
|
4
Amicus Therapeutics
FOLD
$2.34B
| $182M | 9.52% | 7,867,114 | – | – |
|
|
ABMD
5
DELISTED
Abiomed Inc
ABMD
| $180M | 9.46% | 556,633 +52,600 | +10% | +$17.1M |
|
|
6
Acadia Pharmaceuticals
ACAD
$4.38B
| $123M | 6.45% | 2,301,477 +469,177 | +26% | +$25.1M |
|
7
United Therapeutics
UTHR
$13.8B
| $119M | 6.25% | 785,406 | – | – |
|
8
Karyopharm Therapeutics
KPTI
$61.7M
| $81.5M | 4.27% | 5,267,652 +181,500 | +4% | +$2.81M |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $78.7M | 4.12% | 503,429 +45,900 | +10% | +$7.17M |
|
|
RVNC
10
DELISTED
Revance Therapeutics, Inc.
RVNC
| $75.8M | 3.97% | 2,673,313 +678,408 | +34% | +$19.2M |
|
|
EPZM
11
DELISTED
Epizyme, Inc
EPZM
| $73.2M | 3.84% | 6,738,913 +335,313 | +5% | +$3.64M |
|
|
12
Biogen
BIIB
$19.4B
| $57.4M | 3.01% | +234,300 | New | +$57.4M |
|
13
Vanda Pharmaceuticals
VNDA
$279M
| $55.6M | 2.91% | 4,230,548 +60,267 | +1% | +$792K |
|
|
SAGE
14
DELISTED
Sage Therapeutics
SAGE
| $51.1M | 2.68% | 590,200 | – | – |
|
|
15
eHealth
EHTH
$118M
| $41.4M | 2.17% | 586,999 +306,561 | +109% | +$21.6M |
|
16
Align Technology
ALGN
$10.3B
| $36.1M | 1.89% | 67,505 | – | – |
|
|
CLVS
17
DELISTED
Clovis Oncology, Inc.
CLVS
| $21.5M | 1.12% | 4,469,411 | – | – |
|
18
Prothena Corp
PRTA
$441M
| $20.3M | 1.07% | 1,691,805 +363,071 | +27% | +$4.36M |
|
19
Gossamer Bio
GOSS
$562M
| $16.8M | 0.88% | 1,739,050 +661,850 | +61% | +$6.4M |
|
20
Puma Biotechnology
PBYI
$254M
| $14.1M | 0.74% | 1,373,897 +5,580 | +0.4% | +$57.3K |
|
21
AnaptysBio
ANAB
$569M
| $8.95M | 0.47% | 416,292 +47,570 | +13% | +$1.02M |
|
|
DRNA
22
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $7.31M | 0.38% | 331,813 | – | – |
|
|
KLDO
23
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $7.16M | 0.38% | 786,400 | – | – |
|
24
Syndax Pharmaceuticals
SNDX
$1.41B
| $5.88M | 0.31% | 264,200 +65,800 | +33% | +$1.46M |
|
25
Travere Therapeutics
TVTX
$1.56B
| $4.3M | 0.23% | 157,900 | – | – |
|